| Company Name: |
TargetMol Chemicals Inc.
|
| Tel: |
15002134094 |
| Email: |
marketing@targetmol.cn |
| Products Intro: |
Product Name:Cefepime chloride
CAS:107648-79-3
Package:100mg/RMB 17500;50mg/RMB 13800;25mg/RMB 10600
|
Pyrrolidinium, 1-[[(6R,7R)-7-[[(2Z)-2-(2-amino-4-thiazolyl)-2-(methoxyimino)acetyl]amino]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl]-1-methyl-, chloride (1:1) manufacturers
- Cefepime chloride
-
- $2500.00 / 100mg
-
2025-10-27
- CAS:107648-79-3
- Min. Order:
- Purity:
- Supply Ability: 10g
|
| | Pyrrolidinium, 1-[[(6R,7R)-7-[[(2Z)-2-(2-amino-4-thiazolyl)-2-(methoxyimino)acetyl]amino]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl]-1-methyl-, chloride (1:1) Basic information |
| | Pyrrolidinium, 1-[[(6R,7R)-7-[[(2Z)-2-(2-amino-4-thiazolyl)-2-(methoxyimino)acetyl]amino]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl]-1-methyl-, chloride (1:1) Chemical Properties |
| | Pyrrolidinium, 1-[[(6R,7R)-7-[[(2Z)-2-(2-amino-4-thiazolyl)-2-(methoxyimino)acetyl]amino]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl]-1-methyl-, chloride (1:1) Usage And Synthesis |
| Uses | Cefepime (BMY-28142) chloride is a broad-spectrum and cross the blood-brain barrier cephalosporin. Cefepime chloride shows antibacterial effects against both Gram-positive and Gram-negative aerobic bacteria. Cefepime chloride induces neurotoxicity[1][2][3][4]. | | in vivo | Cefepime chloride (80 mg/kg; i.p.) significantly increases the half-life and mice surviveed[4]. | Animal Model: | Male CD-1 mice[4] | | Dosage: | 80 mg/kg | | Administration: | I.p. | | Result: | Significantly prolonged the half-life of cefepime and all mice survived at 18-22 mg/kg cisplatin, and when pretreatment with 26 mg/kg cisplatin significantly decreased survival with the half-life of cefepime was not significantly longer than of 18 mg/kg cisplatin. |
| | IC 50 | β-lactam | | References | [1] Yahav D, et al. Efficacy and safety of cefepime: a systematic review and meta-analysis. Lancet Infect Dis. 2007 May;7(5):338-48. DOI:10.1016/S1473-3099(07)70109-3
[2] Barradell LB, Bryson HM. Cefepime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs. 1994;47(3):471-505. DOI:10.2165/00003495-199447030-00007
[3] Payne LE, et al. Cefepime-induced neurotoxicity: a systematic review. Crit Care. 2017 Nov 14;21(1):276. doi: 10.1186/s13054-017-1856-1. DOI:10.1186/s13054-017-1856-1
[4] Máthé A, et al. The effect of different doses of cisplatin on the pharmacokinetic parameters of cefepime in mice. Lab Anim. 2006 Jul;40(3):296-300. DOI:10.1258/002367706777611514 |
| | Pyrrolidinium, 1-[[(6R,7R)-7-[[(2Z)-2-(2-amino-4-thiazolyl)-2-(methoxyimino)acetyl]amino]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl]-1-methyl-, chloride (1:1) Preparation Products And Raw materials |
|